STOCK TITAN

Fosun International Wins "The Asset ESG Corporate Awards 2024 - Platinum Award" and "Best Initiative in Social Responsibility" from The Asset

Rhea-AI Impact
(No impact)
Rhea-AI Sentiment
(Very Positive)
Tags

Fosun International (HKEX: 00656) has been awarded The Asset ESG Corporate Awards 2024 - Platinum Award and Best Initiative in Social Responsibility at a ceremony in Singapore. The company's ESG strategy 'Create IMPACT' demonstrates its commitment to sustainable development.

Fosun has achieved significant milestones in ESG performance, being the only Greater China conglomerate rated AA by MSCI ESG Ratings and ranking in the top 1% of S&P Global's Sustainability Yearbook 2024 (China Edition). The company's innovations include breakthrough medical treatments, with Fosun Pharma's artesunate injection treating over 68 million malaria patients globally.

The company's 'WE Volunteer' program has engaged over 4,500 employees in public welfare activities, contributing 34,476 hours. Through Fosun Foundation, established in 2012, the company supports various social initiatives, including the Rural Doctors Program which has benefited 3 million grassroots families.

Fosun International (HKEX: 00656) ha ricevuto il Platinum Award degli Asset ESG Corporate Awards 2024 e il miglior'iniziativa di responsabilità sociale in una cerimonia a Singapore. La strategia ESG dell'azienda, chiamata 'Create IMPACT', dimostra il suo impegno per uno sviluppo sostenibile.

Fosun ha raggiunto traguardi significativi nelle prestazioni ESG, essendo l'unico conglomerato della Grande Cina valutato AA da MSCI ESG Ratings e classificandosi tra il 1% migliore dell'S&P Global's Sustainability Yearbook 2024 (Edizione Cina). Le innovazioni dell'azienda includono trattamenti medici all'avanguardia, con l'iniezione di artesunato della Fosun Pharma che ha trattato oltre 68 milioni di pazienti affetti da malaria a livello globale.

Il programma 'WE Volunteer' dell'azienda ha coinvolto oltre 4.500 dipendenti in attività di pubblica beneficenza, contribuendo con 34.476 ore. Attraverso la Fosun Foundation, istituita nel 2012, l'azienda supporta varie iniziative sociali, incluso il Programma per Dottori Rurali che ha beneficiato 3 milioni di famiglie nelle zone rurali.

Fosun International (HKEX: 00656) ha recibido el Platinum Award de los Asset ESG Corporate Awards 2024 y la mejor iniciativa en responsabilidad social en una ceremonia en Singapur. La estrategia ESG de la empresa, denominada 'Create IMPACT', demuestra su compromiso con el desarrollo sostenible.

Fosun ha alcanzado hitos significativos en su desempeño ESG, siendo el único conglomerado de la Gran China calificado AA por MSCI ESG Ratings y ocupando el 1% superior del Sustainability Yearbook 2024 de S&P Global (Edición China). Las innovaciones de la empresa incluyen tratamientos médicos innovadores, con la inyección de artesunato de Fosun Pharma que ha tratado a más de 68 millones de pacientes con malaria a nivel mundial.

El programa 'WE Volunteer' de la empresa ha involucrado a más de 4,500 empleados en actividades de bienestar público, contribuyendo con 34,476 horas. A través de la Fosun Foundation, establecida en 2012, la empresa apoya diversas iniciativas sociales, incluido el Programa de Médicos Rurales que ha beneficiado a 3 millones de familias de base.

포순 인터내셔널 (HKEX: 00656)은 싱가포르에서 열린 시상식에서 2024년 자산 ESG 기업 어워드 - 플래티넘 어워드사회적 책임 최우수 이니셔티브를 수상했습니다. 회사의 ESG 전략인 'Create IMPACT'는 지속 가능한 발전에 대한 헌신을 보여줍니다.

포순은 ESG 성과에서 중요한 이정표를 달성했으며, MSCI ESG 등급에서 AA 등급을받은 유일한 중화권 대기업이며 S&P 글로벌의 지속 가능성 연감 2024 (중국판)에서 상위 1%에 포함되었습니다. 회사의 혁신에는 포순 파마의 아르테수네이트 주사가 있는 의학적 혁신이 포함되어 있으며, 이는 전 세계적으로 6,800만 명 이상의 말라리아 환자를 치료했습니다.

회사의 'WE Volunteer' 프로그램은 4,500명이 넘는 직원들이 공공 복지 활동에 참여하도록 하여 34,476시간을 기여했습니다. 2012년에 설립된 포순 재단을 통해 회사는 300만 가정에 혜택을 준 농촌 의사 프로그램을 포함한 다양한 사회적 이니셔티브를 지원합니다.

Fosun International (HKEX: 00656) a reçu le Platinum Award des Asset ESG Corporate Awards 2024 et la meilleure initiative en responsabilité sociale lors d'une cérémonie à Singapour. La stratégie ESG de l'entreprise, intitulée 'Create IMPACT', démontre son engagement en faveur du développement durable.

Fosun a atteint des jalons significatifs en matière de performance ESG, étant le seul conglomérat de Grande Chine noté AA par MSCI ESG Ratings et se classant parmi le 1% supérieur du Sustainability Yearbook 2024 de S&P Global (Édition Chine). Les innovations de l'entreprise incluent des traitements médicaux révolutionnaires, avec l'injection d'artésunate de Fosun Pharma qui a traité plus de 68 millions de patients atteints de malaria dans le monde.

Le programme 'WE Volunteer' de l'entreprise a engagé plus de 4 500 employés dans des activités de bien-être public, contribuant ainsi à 34 476 heures. À travers la Fosun Foundation, créée en 2012, l'entreprise soutient diverses initiatives sociales, y compris le Programme des médecins ruraux qui a bénéficié à 3 millions de familles de base.

Fosun International (HKEX: 00656) wurde in einer Zeremonie in Singapur mit dem Platinum Award der Asset ESG Corporate Awards 2024 und der besten Initiative für soziale Verantwortung ausgezeichnet. Die ESG-Strategie des Unternehmens 'Create IMPACT' demonstriert sein Engagement für nachhaltige Entwicklung.

Fosun hat bedeutende Meilensteine in der ESG-Performance erreicht und ist der einzige Konglomerat aus Greater China, das von MSCI ESG Ratings mit AA bewertet wurde, und belegt den Platz im oberen 1% des S&P Global's Sustainability Yearbook 2024 (China Edition). Die Innovationen des Unternehmens umfassen bahnbrechende medizinische Behandlungen, wobei die Artesunat-Injektion von Fosun Pharma über 68 Millionen Malariapatienten weltweit behandelt hat.

Das Programm 'WE Volunteer' des Unternehmens hat über 4.500 Mitarbeiter in öffentliche Wohlfahrtsaktivitäten eingebunden und insgesamt 34.476 Stunden beigetragen. Durch die 2012 gegründete Fosun Foundation unterstützt das Unternehmen verschiedene soziale Initiativen, einschließlich des Programms für ländliche Ärzte, von dem 3 Millionen Grundfamilien profitiert haben.

Positive
  • None.
Negative
  • None.

HONG KONG, Nov. 11, 2024 /PRNewswire/ -- On the evening of 7 November 2024, The Asset, a renowned Asian financial magazine, held "The Asset ESG Corporate Awards 2024" awards ceremony at the Four Seasons Hotel Singapore. Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was awarded "The Asset ESG Corporate Awards 2024 – Platinum Award" and "Best Initiative in Social Responsibility".

Organized by The Asset, "The Asset ESG Corporate Awards" has been running for many years and is one of the leading environmental, social and governance (ESG) awards in the Asia-Pacific region. This year, Fosun International was accredited with the Platinum Award at "The Asset ESG Corporate Awards 2024", reflecting the magazine's recognition of Fosun's outstanding performance in various fields including financial performance, corporate governance, social responsibility, environmental protection, investor relations, information disclosure and corporate communication. Other recipients of the Platinum Award include Bank of China (Hong Kong), China Overseas Land and Investment, China Unicom, Kerry Properties, Link Asset Management, Shui On Land, etc.

Fosun's remarkable ESG performance has been widely recognized by the international market

Looking back on the past, Fosun has always paid attention to the reform and development of the global policies in the field of sustainable development. It has established a comprehensive ESG management system, integrated ESG management requirements into business management over the years, actively responded to national and global strategies in relation to sustainable development, ensured information security, promoted technology innovation, implemented "dual carbon" goals, protected the rights and interests of employees to promote sustainable management and value creation.

This year, Fosun has formulated its sustainable development strategy: "Create IMPACT", which stands for I: Innovation-driven, M: Mindful Operation, P: People and Partner Oriented, A: Advanced Governance, C: Climate and Planet Positive and T: Transparency. It is derived from Fosun's original aspiration and is a guarantee of the long-term ESG practices.

In recent years, Fosun has shown outstanding performance in various aspects of ESG. Presently, Fosun International is the only conglomerate in Greater China rated AA by MSCI ESG Ratings. Fosun International outperformed 94% of its global peers in the S&P Global Corporate Sustainability Assessment, and was included in S&P Global's Sustainability Yearbook 2024. Fosun International was also ranked top 1% in S&P Global's Sustainability Yearbook 2024 (China Edition) and recognized as an "Industry Mover". It received an HSI ESG rating of AA- and has been included in the Hang Seng Corporate Sustainability Index for years. Furthermore, Fosun International's FTSE Russell ESG score was consistently higher than the global industry average and it has been continuously selected as a constituent stock of the FTSE4Good Index Series.

Leveraging innovation to actively contribute to society

Fosun adheres to the innovation-driven strategy and actively facilitates its businesses to achieve innovative results so as to make greater contributions to society. Thanks to the long-term accumulated technology innovation capabilities, Fosun has continued to realize the "world's first" and "China's first" achievements. Fosun Pharma's self-developed artesunate for injection treated more than 68 million patients with severe malaria around the world as of the end of 2023. Its second-generation artesunate for injection (Argesun®) is the first injectable artesunate presented with a single solvent system which was prequalified by the World Health Organization (WHO-PQ) for treatment of malaria.

HANQUYOU (trastuzumab for injection), independently developed and manufactured by Shanghai Henlius, the biomedical platform of Fosun Pharma, received marketing approval from the U.S., making it a "Chinese" monoclonal antibody biosimilar approved in China, the European Union (EU), and the U.S. HANSIZHUANG (serplulimab injection), independently developed by Shanghai Henlius, is the world's first anti-PD-1 monoclonal antibody approved for first-line treatment of extensive-stage small cell lung cancer (SCLC). Yi Kai Da (ejilunsai injection), developed by Fosun Kite, is the first CAR-T cell therapy product approved for marketing in China, and has been approved for second-line indication, bringing more treatment options and hope for Chinese lymphoma patients. Intuitive Fosun's domestic Da Vinci Xi Surgical System was successfully approved by the National Medical Products Administration (NMPA) and officially commenced production, realizing "made in China, joint R&D, global sales".

In order to better promote the fulfillment and implementation of corporate social responsibility (CSR), Fosun Foundation was established in 2012. It has been making unremitting efforts in the fields of global emergency relief, rural revitalization, health, education, culture and art, youth development, etc. to create social value. Of which, since its launch at the end of 2017, Fosun Foundation's Rural Doctors Program has covered 78 counties in 16 provinces, municipalities, and autonomous regions across the country, supporting 25,000 rural doctors and benefiting 3 million grassroots families.

The Asset recognized the "WE Volunteer" program, commending Fosun's commitment to "Make A Lasting Impact Together"

Fosun always upholds the core value of "people and partner oriented" and places a strong emphasis on the health and well-being of its employees. In addition to employee care, the Group integrates and leverages resources from Fosun's ecosystem and global operations, joining hands with member companies to launch public welfare activities. At the beginning of 2023, Fosun officially incorporated the half-day public welfare leave policy into the Group's employee manual. Since its implementation one year ago, a total of more than 4,500 Fosun employees at home and abroad have participated in public welfare activities in various fields, amounting to 34,476 hours.

To fulfill Fosun's commitment of 30,000 annual volunteer hours by its employees, and to uphold the original aspirations of "Self-improvement, Teamwork, Performance, and Contribution to Society", Fosun launched the "WE Volunteer" employee volunteer program. Each month, the program features a different theme and invites Fosun ecosystem partners to initiate a series of activities that leverage their unique resources and CSR goals. This initiative aims to engage all Fosun employees and foster collaboration, building a more open and inclusive corporate CSR culture. This year, The Asset recognized the "WE Volunteer" CSR program, commending Fosun for actively encouraging its ecosystem enterprises to embrace social responsibility and promoting the spirit of "Make A Lasting Impact Together".

 

Cision View original content:https://www.prnewswire.com/news-releases/fosun-international-wins-the-asset-esg-corporate-awards-2024--platinum-award-and-best-initiative-in-social-responsibility-from-the-asset-302301961.html

SOURCE Fosun

FAQ

What awards did Fosun International (FOSUY) receive at The Asset ESG Corporate Awards 2024?

Fosun International received two awards: The Asset ESG Corporate Awards 2024 - Platinum Award and Best Initiative in Social Responsibility at the ceremony held on November 7, 2024.

How many volunteer hours did Fosun International's employees contribute in 2023?

Fosun International's employees contributed 34,476 volunteer hours through the WE Volunteer program, with over 4,500 employees participating in various public welfare activities.

What is Fosun International's ESG strategy called?

Fosun International's ESG strategy is called 'Create IMPACT', which stands for Innovation-driven, Mindful Operation, People and Partner Oriented, Advanced Governance, Climate and Planet Positive, and Transparency.

How many patients has Fosun Pharma's artesunate injection treated globally?

Fosun Pharma's artesunate injection has treated more than 68 million patients with severe malaria worldwide as of the end of 2023.

FOSUN INTL LTD UNSP/ADR

OTC:FOSUY

FOSUY Rankings

FOSUY Latest News

FOSUY Stock Data

4.77B
2.19B
Conglomerates
Industrials
Link
United States of America
Central